A systematic review in 2022 analyzing data from 12 recent randomized controlled trials demonstrated improvement in key clinical parameters, including forced expiratory volume in 1 second (FEV1), asthma control questionnaire (ACQ) scores, fractional exhaled nitric oxide (FENO) levels, and immunoglobulin E (IgE) levels at both 12 and 24 weeks of treatment [4]. The gene discussed is IGHE; the disease is asthma.